Wedbush Maintains an 'Outperform' on Savient Pharmaceuticals (SVNT); Raising PT on Potential Takeout in the Near Term
Tweet Send to a Friend
Wedbush maintains an 'Outperform' rating on Savient Pharmaceuticals (Nasdaq: SVNT), raises PT from $20 to $25.
Wedbush analyst says, "Yesterday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "Yesterday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
